Beyond amyloid: The next generation of Alzheimer's disease therapeutics

Molecular Interventions

Volumn 7, Issue 5, 2007, Pages 261-270

  Seabrook, Guy R ^a   Ray, William J ^a   Shearman, Mark ^a   Hutton, Michael ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; ABT 560; AC 1202; AL 108; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AQW 051; AVE 1625; AVE 8122; AZD 1080; AZD 3480; BF 2649; CX 717; DIMEBON; EHT 0202; EVT 101; GT 1061; GW 189254; GW 239512; HF 0220; HT 0712; ISPRONICLINE; JNJ 17216498; KETASYN; LADOSTIGIL; LECOZOTAN; LEUPRORELIN; LX 6171; MEM 1003; MEM 3454; NGX 267; NP 031112; PRX 03140; PRX 07034; PRX 07037; PYM 50028; SAM 315; SAM 531; SGS 518; SR 18711; SR 57667; SRA 444; SYN 114; T 817; TAU PROTEIN; TTP 488; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 025; XALIPRODEN;

ALZHEIMER DISEASE; AUTOPSY; BIOACCUMULATION; CADAVER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HUMAN; NEUROPATHOLOGY; POPULATION RESEARCH; PROTEIN TARGETING; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DRUG DESIGN; HUMANS; NEUROTRANSMITTER AGENTS; RISK FACTORS;

EID: 35348936103     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.7.5.8     Document Type: Review

References (80)

1. Kola, I. and Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
2. Roberson, E.D. and Mucke, L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science 314, 781-784 (2006).
3. Walsh, D.M. and Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193 (2004).
4. Lee, V.M., Goedert, M., and Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 24, 1121-1159 (2001).
5. Hardy, J. Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal. J. Alzheimers Dis. 9, 151-153 (2006).
6. Holtzman, D.M., Bales, K.R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A.M., Chang, L.K., Sun, Y., and Paul, S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103, R15-R21 (1999).
7. Josephs, K.A., Tsuboi, Y., Cookson, N., Watt, H., and Dickson, D.W. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch. Neurol. 61, 1579-1584 (2004). One of several neuropathological studies that have established that the ε4 allele of APOE enhances, regardless of clinical diagnosis, amyloid deposition in patients.
8. Vidal, R., Frangione, B., Rostagno, A., Mead, S., Revesz, T., Plant, G., and Ghiso, J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399, 776-781 (1999).
9. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
10. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., and Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
11. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., and Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (2007).
12. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
13. Holcomb, L., Gordon, M.N., McGowan, E. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Nat. Med. 4, 97-100 (1998).
14. Chapman, P.F., White, G.L., Jones, M.W. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276 (1999).
15. Fitzjohn, S.M., Morton, R.A., Kuenzi, F. et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21, 4691-4698 (2001).
16. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. APP processing and synaptic function. Neuron 37, 925-937 (2003).
17. Palop, J.J., Chin, J., Roberson, E.D. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711 (2007).
18. Best, J.D., Smith, D.W., Reilly, M.A. et al. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclo hexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther. 320, 552-558 (2007).
19. Lindsley, S.R., Moore, K.P., Rajapakse, H.A. et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 17, 4057-4061 (2007).
20. Braak, H. and Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol.(Berl) 82, 239-259 (1991).
21. Braak, E., Griffing, K., Arai, K., Bohl, J., Bratzke, H., and Braak, H. Neuropathology of Alzheimer's disease: What is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 249 Suppl 3, 14-22 (1999).
22. Carter, J. and Lippa, C.F. Beta-amyloid, neuronal death and Alzheimer's disease. Curr. Mol. Med. 1, 733-737 (2001).
23. Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., and Buxbaum, J.D. Correlation between elevated levels of amyloid-beta peptide in the brain and cognitive decline. JAMA 283, 1571-1577 (2000).
24. McGowan, E., Eriksen, J., and Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 22, 281-289 (2006).
25. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat. Med. 9, 448-452 (2003).
26. Patton, R.L., Kalback, W.M., Esh, C.L. et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169, 1048-1063 (2006).
27. Gilman, S., Koller, M., Black, R.S. et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562 (2005).
28. Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S.A., Liao, F.F., Xu, H., and Zhang, Y.W. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 282, 10873-10880 (2007).
29. Szczygielski, J., Mautes, A., Steudel, W.I., Falkai, P., Bayer, T.A., and Wirths, O. Traumatic brain injury: Cause or risk of Alzheimer's disease? A review of experimental studies. J. Neural Transm. 112, 1547-1564 (2005).
30. Zetterberg, H., Hietala, M.A., Jonsson, M. et al. Neurochemical aftermath of amateur boxing. Arch. Neurol. 63, 1277-1280 (2006).
31. Robichaud, A.J. Approaches to palliative therapies for Alzheimer's disease. Curr. Top. Med. Chem. 6, 553-568 (2006).
32. Karlawish, J.H. Donepezil delay to nursing home placement study is flawed. J. Am. Geriatr. Soc. 52, 845-846 (2004).
33. Caccamo, A., Oddo, S., Billings, L.M., Green, K.N., Martinez-Coria, H., Fisher, A., and Laferla, F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682 (2006). The authors demonstrate that the M1 muscarinic agonist AF267B lowers Aβ42, reduces tau hyperphosphorylation, and improves cognition in their triple transgenic model of AD, presumably through a novel indirect amyloid-altering pathway.
34. Fisher, A., Pittel, Z., Haring, R. et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J. Mol. Neurosci. 20, 349-356 (2003).
35. Poorkaj, P., Bird, T.D., Wijsman, E. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998).
36. Hutton, M., Lendon, C.L., Rizzu, P. et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
37. Baker, M., Litvan, I., Houlden, H. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711-715 (1999).
38. Houlden, H., Baker, M., Morris, H.R. et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702-1706 (2001).
39. Reed, L.A., Wszolek, Z.K., and Hutton, M. Phenotypic correlations in FTDP-17. Neurobiol. Aging 22, 89-107 (2001).
40. Dickey, C.A., Kamal, A., Lundgren, K. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648-658 (2007).
41. Pickhardt, M., Larbig, G., Khlistunova, I., Coksezen, A., Meyer, B., Mandelkow, E.M., Schmidt, B., and Mandelkow, E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023 (2007). The most extensive screening study published to date for compounds that inhibit tau aggregation.
42. Zhang, B., Maiti, A., Shively, S. et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA 102, 227-231 (2005).
43. Le Corre, S., Klafki, H.W., Plesnila, N. et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. USA 103, 9673-9678 (2006). Interesting study that reports a non-selective kinase inhibitor that blocks the accumulation of aggregated hyperphosphorylated tau and the development of functional deficits in a widely used model of tauopathy.
44. Noble, W., Planel, E., Zehr, C. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 6990-6995 (2005).
45. Ballatore, C., Lee, V.M., and Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672 (2007).
46. Mazanetz, M.P. and Fischer, P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug. Discov. 6, 464-479 (2007). Comprehensive review of the issues that surround kinase inhibition as a drug target for human tauopathy.
47. Farrer, L.A., Cupples, L.A., Haines, J.L. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
48. Mahley, R.W., Weisgraber, K.H., and Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 5644-5651 (2006).
49. Finehout, E.J., Franck, Z., Choe, L.H., Relkin, N., and Lee, K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61, 120-129 (2007).
50. Budge, M.M., De Jager, C., Hogervorst, E., and Smith, A.D. Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J. Am. Geriatr. Soc. 50, 2014-2018 (2002).
51. Nurk, E., Tell, G.S., Vollset, S.E., Nygard, O., Refsum, H., and Ueland, P.M. Plasma total homocysteine and hospitalizations for cardiovascular disease: The Hordaland Homocysteine Study. Arch. Intern. Med. 162, 1374-1381 (2002).
52. Simonsen, A.H., McGuire, J., Hansson, O., Zetterberg, H., Podust, V.N., Davies, H.A., Waldemar, G., Minthon, L., and Blennow, K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64, 366-370 (2007).
53. Sontag, E., Nunbhakdi-Craig, V., Sontag, J.M., Diaz-Arrastia, R., Ogris, E., Dayal, S., Lentz, S.R., Arning, E., and Bottiglieri, T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci. 27, 2751-2759 (2007).
54. Blain, J.F. and Poirier, J. Cholesterol homeostasis and the pathophysiology of Alzheimer's disease. Expert Rev. Neurother. 4, 823-829 (2004).
55. Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A., and Kazis, L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med, 5, 20 (2007).
56. Grimm, M.O., Grimm, H.S., Patzold, A.J. et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7, 1118-1123 (2005).
57. Riddell, D.R., Zhou, H., Comery, T.A. et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34, 621-628 (2007).
58. Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E.G., Landreth, G.E., Vinters, H.V., and Tontonoz, P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. USA 104, 10601-10606 (2007).
59. Bu, G., Cam, J., and Zerbinatti, C. LRP in amyloid-beta production and metabolism. Ann. NY Acad. Sci. 1086, 35-53 (2006).
60. Kotti, T.J., Ramirez, D.M., Pfeiffer, B.E., Huber, K.M., and Russell, D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA 103, 3869-3874 (2006).
61. Olkkonen, V.M., Johansson, M., Suchanek, M., Yan, D., Hynynen, R., Ehnholm, C., Jauhiainen, M., Thiele, C., and Lehto, M. The OSBP-related proteins (ORPs): global sterol sensors for co-ordination of cellular lipid metabolism, membrane trafficking and signalling processes? Biochem. Soc. Trans. 34, 389-391 (2006).
62. Rapoport, S.I., Hatanpaa, K., Brady, D.R., and Chandrasekaran, K. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration 5, 473-476 (1996).
63. Chen, X., Stern, D., and Yan, S.D. Mitochondrial dysfunction and Alzheimer's disease. Curr. Alzheimer Res. 3, 515-520 (2006).
64. Scarmeas, N. and Stern, Y. Cognitive reserve and lifestyle. J. Clin. Exp. Neuropsychol. 25, 625-633 (2003).
65. Riley, K.P., Snowdon, D.A., Desrosiers, M.F., and Markesbery, W.R. Early life linguistic ability, late life cognitive function, and neuropathology: Findings from the Nun Study. Neurobiol. Aging 26, 341-347 (2005).
66. Adlard, P.A., Perreau, V.M., Pop, V., and Cotman, C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 4217-4221 (2005).
67. Lazarov, O., Robinson, J., Tang, Y.P. et al. Environmental enrichment reduces A-beta levels and amyloid deposition in transgenic mice. Cell 120, 701-713 (2005).
68. Billings, L.M., Green, K.N., McGaugh, J.L., and Laferla, F.M. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci. 27, 751-761 (2007).
69. Velliquette, R.A., O'Connor, T., and Vassar, R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25, 10874-10883 (2005).
70. Risner, M.E., Saunders, A.M., Altman, J.F., Ormandy, G.C., Craft, S., Foley, I.M., Zvartau-Hind, M.E., Hosford, D.A., and Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254 (2006).
71. Strum, J.C., Shehee, R., Virley, D. et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers. Dis. 11, 45-51 (2007).
72. McGeer, P.L., Rogers, J., and McGeer, E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J. Alzheimers Dis. 9, 271-276 (2006).
73. Chow, N., Bell, R.D., Deane, R., Streb, J.W., Chen, J., Brooks, A., Van Nostrand, W., Miano, J.M., and Zlokovic, B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc. Natl. Acad. Sci. USA 104, 823-828 (2007).
74. Majercak, J., Ray, W.J., Espeseth, A. et al. LRRTM3 promotes processing of amyloid precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 17967-17972 (2006). In an elegant example of an unbiased strategy for the identification of new therapeutic targets, the authors use siRNAs to screen 15,200 human genes for involvement in APP processing. LRRTM3, a novel regulator of APP processing, is identified in this work.
75. Park, J.H., Gimbel, D.A., GrandPre, T., Lee, J.K., Kim, J.E., Li, W., Lee, D.H., and Strittmatter, S.M. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J. Neurosci. 26, 1386-1395 (2006).
76. Seabrook, G.R., Smith, D.W., Bowery, B.J. et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38, 349-359 (1999).
77. Torroja, L., Packard, M., Gorczyca, M., White, K., and Budnik, V. The Drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction. J. Neurosci. 19, 7793-7803 (1999).
78. Gralle, M. and Ferreira, S.T. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Prog. Neurobiol. 82, 11-32 (2007).
79. Palop, J.J., Chin, J., and Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768-773 (2006).
80. Crowther, D.C., Page, R., Chandraratna, D., and Lomas, D.A. A Drosophila model of Alzheimer's disease. Methods Enzymol. 412, 234-255 (2006).